Sarepta Therapeutics, Inc.

Historical 13F Holders

Symbol
SRPT
CUSIP
803607100
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 803607100 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 15.8% 7/30/2026
Event 6/30/2026
Vanguard Portfolio Management LLC 13G/A 8.1% 7/31/2026
Event 6/30/2026
State Street Corp 13G 7.0% 11/10/2026
Event 9/30/2026
Vanguard Capital Management LLC 13G 5.1% 4/30/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
D. E. Shaw & Co., L.P. 13G/A
1.9% 11/14/2025
Event 9/30/2025
AQR Capital Management, LLC 13G/A
1.3% 11/13/2026
Event 9/30/2026
Capital International Investors 13G/A 0.5% 8/13/2025
Event 6/30/2025
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 317 105 M $1.91B
2026 Q2 333 108 M $1.93B
2026 Q1 352 103 M $2.24B
2025 Q4 357 93.9 M $2.02B
2025 Q3 332 86.8 M $1.67B
2025 Q2 378 82.8 M $1.42B
2025 Q1 445 88.2 M $5.57B
2024 Q4 475 89.3 M $10.7B
2024 Q3 468 88.2 M $10.8B
2024 Q2 493 88.8 M $14.0B
2024 Q1 422 83.3 M $10.8B
2023 Q4 409 82.0 M $7.92B
2023 Q3 405 83.3 M $10.1B
2023 Q2 417 81.9 M $9.38B
2023 Q1 432 81.2 M $11.2B
2022 Q4 424 78.9 M $10.2B
2022 Q3 382 78.2 M $8.65B
2022 Q2 337 73.4 M $5.50B
2022 Q1 333 73.1 M $5.71B
2021 Q4 350 71.9 M $6.48B
2021 Q3 312 65.8 M $6.08B
2021 Q2 340 64.9 M $5.04B
2021 Q1 371 66.5 M $4.97B
2020 Q4 466 70.8 M $12.1B
2020 Q3 416 71.7 M $10.1B
2020 Q2 419 73.9 M $11.9B
2020 Q1 372 73.7 M $7.21B
2019 Q4 402 73.7 M $9.51B
2019 Q3 354 73.8 M $5.52B
2019 Q2 371 72.1 M $10.9B
2019 Q1 378 71.1 M $8.48B
2018 Q4 346 68.7 M $7.50B
2018 Q3 354 62.0 M $10.0B
2018 Q2 324 60.9 M $8.05B
2018 Q1 277 56.8 M $4.20B
2017 Q4 259 55.2 M $3.07B
2017 Q3 239 53.7 M $2.44B
2017 Q2 195 42.7 M $1.44B
2017 Q1 185 40.8 M $1.21B
2016 Q4 187 39.5 M $1.08B
2016 Q3 198 42.4 M $2.60B
2016 Q2 162 34.6 M $661M
2016 Q1 144 35.1 M $686M
2015 Q4 161 28.5 M $1.10B
2015 Q3 156 27.8 M $892M
2015 Q2 136 26.7 M $811M
2015 Q1 116 24.2 M $321M
2014 Q4 121 24.7 M $359M
2014 Q3 124 26.0 M $548M
2014 Q2 128 26.7 M $794M
2014 Q1 118 26.6 M $639M